- Home
- MBC vs ETON Comparison
MBC vs ETON Comparison
Compare MBC & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBC | ETON |
|---|---|---|
| Founded | 1954 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MBC | ETON |
|---|---|---|
| Price | $9.26 | $40.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.8M | 542.2K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $2,734,700,000.00 | $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | $2.55 | $47.23 |
| P/E Ratio | ★ N/A | $831.60 |
| Revenue Growth | 1.27 | ★ 104.94 |
| 52 Week Low | $6.61 | $14.27 |
| 52 Week High | $14.22 | $50.18 |
Technical Indicators
Market Signals| Indicator | MBC | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 54.89 | 45.96 |
| Support Level | $7.78 | $15.77 |
| Resistance Level | $9.55 | $50.18 |
| Average True Range (ATR) | 0.45 | 2.64 |
| MACD | 0.06 | -0.94 |
| Stochastic Oscillator | 83.23 | 3.29 |
Price Performance
Historical ComparisonAbout MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.